The average reduction in HAM-D scores favored clinical management, at an average difference of 2.26 points.
汉密顿抑郁量表分数的降低支持了临床治疗，平均差别在2.26个百分点。
The 17-item Hamilton Rating Scale for Depression (HAM-D) was also used, with inclusion criteria of a HAM-D score of 20 or higher.
还使用了17项哈米尔顿抑郁测量表（HAM-D），其入围标准是HAM-D得分为20分或者更高的分数。
Over the 12 weeks of treatment, citalopram proved to be superior to placebo, with an average 3.3-point greater reduction in HAM-D scores.
在12周的治疗期间，西酞普兰被证明要好于安慰剂，在汉密顿抑郁量表的得分上要比其低3.3个百分点。
The primary outcomes were the change in the Hamilton Depression Rating Scale(HAM-D) and motor dysfunction rating scale for Parkinson's disease(MDRSPD) in 8 weeks.
评价在8周的时间内汉密尔顿抑郁量及帕金森病运动功能评分量表（MDRSPD）评分的变化。
The response rate, defined as a 50% or greater reduction in HAM-D scores, was higher among patients receiving citalopram, at 35.9% compared with 22.5% for those given placebo.
反应率，定义为在汉密顿抑郁量表的得分上有50%或者更多的减少，要高于那些接受西酞普兰治疗的病人，其结果是35.9%比上22.5%，对于那些给予安慰剂的病人来说。
The response rate, defined as a 50% or greater reduction in HAM-D scores, was higher among patients receiving citalopram, at 35.9% compared with 22.5% for those given placebo.
反应率，定义为在汉密顿抑郁量表的得分上有50%或者更多的减少，要高于那些接受西酞普兰治疗的病人，其结果是35.9%比上22.5%，对于那些给予安慰剂的病人来说。
应用推荐